Jaipur-based Aignosis has raised Rs 4 crore in a seed round co-led by Antler and Zerodha co-founder Nikhil Kamath, with Varun Dua and IIMA Ventures also participating. The product is a laptop-and-webcam screening tool for autism and developmental delay in children, aimed at government health centres and small clinics rather than premium hospitals. By most funding-news conventions, this barely registers - a few hundred thousand dollars is a rounding error against the raises that usually lead a weekly tracker.
It’s also the wrong number to focus on.
The word doing the actual work is “screening”
Aignosis is explicit that its tool generates a risk flag, not a diagnosis - a signal that a child may need a formal clinical assessment, delivered by a system that stops well short of making the call itself. In a category this sensitive, that’s not a legal disclaimer buried in the terms of service. It’s the entire basis on which a government health worker or an overworked paediatrician is willing to let a piece of software anywhere near a child’s development.
A tool that overclaimed - that offered anything resembling a diagnosis - would need an entirely different trust relationship with clinicians, regulators, and parents, one built on the software being right every time. A tool that explicitly says “go get this checked” instead of “here is the answer” is asking for something much easier to grant: permission to flag, not permission to decide. That restraint is the product decision that makes the distribution strategy possible at all.
Why the distribution target is the real signal
Aignosis says it has completed its regulatory process with India’s drug and medical device authority and has already run more than 8,000 screenings, with a target of 100,000 by the end of the next financial year, expanding into states including Punjab, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra. None of that is a premium-clinic rollout. It’s a bet that the biggest gap in developmental screening isn’t technology - it’s the fact that a formal assessment in India usually requires a specialist, a waitlist, and a family that can get to one.
A government health centre or a small-town clinic will not adopt a tool it has to take on faith. It adopts a tool that tells it, plainly, what it is and isn’t qualified to say. Aignosis built the humility into the product before it tried to build the distribution.
What the Kamath name is actually buying
Co-leading a round this size is not primarily a capital decision for an investor like Kamath - it’s a credibility transfer, the same instrument a reference customer or a reputable early design partner provides, just priced in equity instead of a testimonial. For a company trying to get government clinics comfortable with an unfamiliar screening tool, having a widely recognised name attached matters less for the cheque and more for the door it opens with a state health department that has never heard of Aignosis but has certainly heard of Zerodha.
The founders clearly understood this going in. A Rs 4 crore round with this investor list was never going to be covered for its size. It was always going to be covered for who signed it - and for a company selling trust into institutions that have every reason to be skeptical of a new name, that coverage is the actual return.